| 000 | 01764 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250518075218.0 | ||
| 264 | 0 | _c20201106 | |
| 008 | 202011s 0 0 eng d | ||
| 022 | _a1573-742X | ||
| 024 | 7 |
_a10.1007/s11239-019-02014-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGue, Ying X | |
| 245 | 0 | 0 |
_aRationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. _h[electronic resource] |
| 260 |
_bJournal of thrombosis and thrombolysis _cFeb 2020 |
||
| 300 |
_a192-198 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aAcute Coronary Syndrome _xblood |
| 650 | 0 | 4 |
_aClopidogrel _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDual Anti-Platelet Therapy _xmethods |
| 650 | 0 | 4 |
_aFactor Xa Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinolysis _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aRivaroxaban _xadministration & dosage |
| 650 | 0 | 4 |
_aThrombelastography _xmethods |
| 650 | 0 | 4 |
_aThrombosis _xblood |
| 650 | 0 | 4 |
_aTicagrelor _xadministration & dosage |
| 700 | 1 | _aKanji, Rahim | |
| 700 | 1 | _aWellsted, David M | |
| 700 | 1 | _aSrinivasan, Manivannan | |
| 700 | 1 | _aWyatt, Solange | |
| 700 | 1 | _aGorog, Diana A | |
| 773 | 0 |
_tJournal of thrombosis and thrombolysis _gvol. 49 _gno. 2 _gp. 192-198 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11239-019-02014-5 _zAvailable from publisher's website |
| 999 |
_c30454998 _d30454998 |
||